Physician profile
Thomas M Weber
NPI 1093753279
$358.00
in general payments reported to CMS, 2019-2025
11 companies · $68.84 in 2025
The $68.84 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $44.20 · 2021: $17.17 · 2022: $27.77 · 2024: $62.00 · 2025: $68.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $131.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $130.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $52.41 | 2019 | |
| Boston Scientific Corporation | $50.80 | 2022-2024 | Lux-Dx Insertable Cardiac Monitor |
| Regeneron Healthcare Solutions, INC. | $49.62 | 2025 | Dupixent |
| Inspire Medical Systems, INC. | $38.97 | 2024 | Inspire |
| Shire North American Group INC | $37.24 | 2019 | |
| Electromed, INC. | $34.42 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $34.14 | 2019-2020 | |
| Avadel Cns Pharmaceuticals, LLC | $19.22 | 2025 | Lumryz |
| Circassia INC. | $16.59 | 2019 | |
| Philips North America LLC | $13.03 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Weber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.